MX2011012047A - Inmunoglobulinas humanas anti-cd52. - Google Patents

Inmunoglobulinas humanas anti-cd52.

Info

Publication number
MX2011012047A
MX2011012047A MX2011012047A MX2011012047A MX2011012047A MX 2011012047 A MX2011012047 A MX 2011012047A MX 2011012047 A MX2011012047 A MX 2011012047A MX 2011012047 A MX2011012047 A MX 2011012047A MX 2011012047 A MX2011012047 A MX 2011012047A
Authority
MX
Mexico
Prior art keywords
humanized
humanized immunoglobulin
immunoglobulins
relates
human
Prior art date
Application number
MX2011012047A
Other languages
English (en)
Spanish (es)
Inventor
Bruce L Roberts
William M Siders
Srinivas Shankara
William Harold Brondyk
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011012047(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2011012047A publication Critical patent/MX2011012047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
MX2011012047A 2009-05-13 2010-05-13 Inmunoglobulinas humanas anti-cd52. MX2011012047A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17783709P 2009-05-13 2009-05-13
PCT/US2010/034704 WO2010132659A2 (en) 2009-05-13 2010-05-13 Anti-human cd52 immunoglobulins

Publications (1)

Publication Number Publication Date
MX2011012047A true MX2011012047A (es) 2011-12-14

Family

ID=43085579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012047A MX2011012047A (es) 2009-05-13 2010-05-13 Inmunoglobulinas humanas anti-cd52.

Country Status (19)

Country Link
US (5) US8617554B2 (cg-RX-API-DMAC7.html)
EP (3) EP2998405B1 (cg-RX-API-DMAC7.html)
JP (4) JP5894912B2 (cg-RX-API-DMAC7.html)
KR (5) KR20140102764A (cg-RX-API-DMAC7.html)
CN (3) CN110016081A (cg-RX-API-DMAC7.html)
AR (1) AR076770A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010249003B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1013085A2 (cg-RX-API-DMAC7.html)
CA (2) CA2939492C (cg-RX-API-DMAC7.html)
HK (2) HK1222682A1 (cg-RX-API-DMAC7.html)
IL (2) IL216141B (cg-RX-API-DMAC7.html)
MX (1) MX2011012047A (cg-RX-API-DMAC7.html)
MY (1) MY160126A (cg-RX-API-DMAC7.html)
NZ (2) NZ596384A (cg-RX-API-DMAC7.html)
RU (2) RU2603743C2 (cg-RX-API-DMAC7.html)
SG (2) SG176060A1 (cg-RX-API-DMAC7.html)
TW (3) TWI614267B (cg-RX-API-DMAC7.html)
WO (1) WO2010132659A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201108077B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9669057B2 (en) 2008-04-25 2017-06-06 Duke University Regulatory B cells and their uses
KR20140102764A (ko) 2009-05-13 2014-08-22 겐자임 코포레이션 항-인간 ｃｄ52 면역글루불린
JP5834004B2 (ja) 2009-05-13 2015-12-16 ジェンザイム・コーポレーション ループス治療のための方法および組成物
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
JP6104794B2 (ja) 2011-04-18 2017-03-29 国立大学法人 東京大学 抗ｉｔｍ２ａ抗体を用いる癌の診断および治療
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
ES3033729T3 (en) 2011-10-28 2025-08-07 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2013185165A1 (en) * 2012-06-14 2013-12-19 The Walter And Eliza Hall Institute Of Medical Research Cd-52 antibodies and their use in determining and enhancing an immune response in a subject
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2014066271A1 (en) * 2012-10-22 2014-05-01 Becton, Dickinson And Company Non-b-lineage cells capable of producing antibody
WO2014165282A1 (en) 2013-03-12 2014-10-09 Institute of Arthritis Research, LLC Immunologically active polypeptide
CN105121465B (zh) 2013-03-13 2020-09-08 普罗塞纳生物科技公司 Tau免疫疗法
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
KR102042174B1 (ko) 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
KR102186363B1 (ko) * 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) * 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
TW201717935A (zh) 2015-06-03 2017-06-01 波士頓生醫公司 用於治療癌症的組成物和方法
FI3452507T3 (fi) 2016-05-02 2022-12-15 Tau-immuunihoito
WO2017191561A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
IL262726B2 (en) 2016-05-02 2024-07-01 Prothena Biosciences Ltd Antibodies recognizing tau
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CN110248668B (zh) 2016-12-15 2023-05-30 杜克大学 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
EP3612564A2 (en) * 2017-04-21 2020-02-26 Genzyme Corporation Treatment of multiple sclerosis with anti-cd52 antibodies
IL270375B2 (en) 2017-05-02 2024-12-01 Prothena Biosciences Ltd Antibodies recognizing tau
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
KR20200103751A (ko) * 2017-12-20 2020-09-02 라디뮨 테라퓨틱스 인코포레이티드 센트린-1에 대한 항체, 이의 제조 방법, 및 용도
JP7498714B2 (ja) * 2018-12-19 2024-06-12 ヒューマブス・バイオメッド・ソシエテ・アノニム Ｂ型肝炎ウイルスを中和する抗体およびその使用
EP3897672B1 (en) 2018-12-20 2023-08-09 VIR Biotechnology, Inc. Combination hbv therapy
KR20210134943A (ko) 2019-03-03 2021-11-11 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN109929835A (zh) * 2019-03-27 2019-06-25 中国人民解放军第四军医大学 一种鼠单克隆抗体功能轻链可变区基因的扩增方法
KR102878895B1 (ko) 2019-05-21 2025-10-31 노파르티스 아게 Cd19 결합 분자 및 이의 용도
MX2021015670A (es) * 2019-07-02 2022-04-18 Telix Int Pty Ltd Anticuerpos contra caix con afinidad reducida por el receptor de fc neonatal.
TWI800824B (zh) * 2020-05-08 2023-05-01 大陸商亘喜生物科技（上海）有限公司 一種抗cd19抗體的抗體及其製備和應用
JP2023554593A (ja) * 2020-11-19 2023-12-28 ジェンザイム・コーポレーション フローサイトメトリー減弱レポーター発現（ｆｌｏｗ ｃｙｔｏｍｅｔｒｙ ａｔｔｅｎｕａｔｅｄ ｒｅｐｏｒｔｅｒ ｅｘｐｒｅｓｓｉｏｎ）（ｆｌａｒｅ）マルチレポーター系およびその使用方法
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2025031965A1 (en) * 2023-08-04 2025-02-13 Cimeio Therapeutics Ag Discernible cell surface protein variants of cd52 for use in cell therapy

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPH0684377B2 (ja) 1986-04-17 1994-10-26 協和醗酵工業株式会社 新規化合物ｄｃ―８８ａ及びｄｃ―８９ａ１
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP0328404B1 (en) 1988-02-12 1993-09-29 Btg International Limited Modified antibodies
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9108056D0 (en) * 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
ES2220927T3 (es) 1994-04-22 2004-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de dc-89.
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
AU765588C (en) 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
NZ521182A (en) 2000-03-03 2004-11-26 Cambridge Antibody Tech Human antibodies against eotaxin comprising VH adn VL domains and their use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) * 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2004042032A2 (en) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) * 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
KR20060002896A (ko) * 2003-03-31 2006-01-09 기린 비루 가부시키가이샤 항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
ATE552276T1 (de) 2003-11-01 2012-04-15 Merck Patent Gmbh Modifizierter anti-cd52-antikörper
US20060204496A1 (en) * 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
KR101247908B1 (ko) * 2004-09-02 2013-03-26 제넨테크, 인크. 항-ｆｃ-감마 ｒｉｉｂ 수용체 항체 및 그의 용도
PL1850873T3 (pl) 2005-02-08 2019-06-28 Genzyme Corporation Przeciwciała przeciwko tgfbeta
JP2009504136A (ja) * 2005-05-24 2009-02-05 アベスタゲン リミテッド 慢性リンパ性白血病治療のためのｃｄ５２に対するモノクローナル抗体産生のための組み換え法
SI2460831T1 (sl) 2005-05-27 2017-01-31 Biogen Ma Inc. Protitelesa, ki se vežejo na TWEAK
JP2009521909A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ＩＬ−６とＩＬ−６Ｒαの複合体のｇｐ１３０への結合を阻害する抗ＩＬ−６抗体
EP2012814B1 (en) * 2006-04-12 2013-05-22 Genzyme Corporation Methods of treating autoimmune diseases
KR101583587B1 (ko) 2006-09-13 2016-01-08 젠자임 코포레이션 캠패스-1ｈ에 의한 다발성 경화증 (ｍｓ)의 치료
US20100135998A1 (en) 2007-02-28 2010-06-03 Schering Corporation Combination therapy for treatment of immune disorders
CA2689408A1 (en) * 2007-06-22 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
KR20140102764A (ko) 2009-05-13 2014-08-22 겐자임 코포레이션 항-인간 ｃｄ52 면역글루불린
JP5834004B2 (ja) 2009-05-13 2015-12-16 ジェンザイム・コーポレーション ループス治療のための方法および組成物
US20120058082A1 (en) 2009-05-13 2012-03-08 Genzyme Corporation Methods and compositions for treatment
SG177653A1 (en) 2009-07-15 2012-02-28 Aimm Therapeutics Bv Gram-positive bacteria specific binding compounds
MX360336B (es) 2010-07-16 2018-10-30 Adimab Llc Star Colecciones de anticuerpos.
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
PL3204425T3 (pl) 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
EP3612564A2 (en) 2017-04-21 2020-02-26 Genzyme Corporation Treatment of multiple sclerosis with anti-cd52 antibodies

Also Published As

Publication number Publication date
CA2761800C (en) 2016-09-27
CA2939492A1 (en) 2010-11-18
KR101537840B1 (ko) 2015-07-22
KR20160005143A (ko) 2016-01-13
KR20170113704A (ko) 2017-10-12
BRPI1013085A2 (pt) 2020-11-03
NZ621170A (en) 2015-08-28
US11945874B2 (en) 2024-04-02
AR076770A1 (es) 2011-07-06
KR20120111932A (ko) 2012-10-11
EP3683317A2 (en) 2020-07-22
TW201043694A (en) 2010-12-16
US20220010024A1 (en) 2022-01-13
IL216141A0 (en) 2012-01-31
JP2016093194A (ja) 2016-05-26
WO2010132659A3 (en) 2011-01-06
KR20160103160A (ko) 2016-08-31
US20120100152A1 (en) 2012-04-26
TWI614267B (zh) 2018-02-11
CA2761800A1 (en) 2010-11-18
ZA201108077B (en) 2013-01-30
IL216141B (en) 2018-11-29
JP2014195474A (ja) 2014-10-16
SG10201608169QA (en) 2016-11-29
MY160126A (en) 2017-02-28
TWI529247B (zh) 2016-04-11
TW201825115A (zh) 2018-07-16
RU2011150516A (ru) 2013-06-20
US20200040091A1 (en) 2020-02-06
CN104231084B (zh) 2019-04-23
CN110016081A (zh) 2019-07-16
NZ596384A (en) 2014-03-28
JP2012526558A (ja) 2012-11-01
KR20140102764A (ko) 2014-08-22
JP5894912B2 (ja) 2016-03-30
JP2018029624A (ja) 2018-03-01
CN104231084A (zh) 2014-12-24
CN102459628A (zh) 2012-05-16
EP3683317A3 (en) 2020-09-30
WO2010132659A2 (en) 2010-11-18
US8617554B2 (en) 2013-12-31
RU2603743C2 (ru) 2016-11-27
EP2429582A4 (en) 2013-01-23
AU2010249003A1 (en) 2011-11-03
IL262639A (en) 2018-12-31
EP2998405A1 (en) 2016-03-23
US20160208010A1 (en) 2016-07-21
EP2429582A2 (en) 2012-03-21
HK1222682A1 (en) 2017-07-07
AU2010249003B2 (en) 2015-08-20
TW201636367A (zh) 2016-10-16
US20140341910A1 (en) 2014-11-20
RU2016142225A (ru) 2018-12-18
SG176060A1 (en) 2011-12-29
HK1205152A1 (en) 2015-12-11
EP2998405B1 (en) 2019-12-11
CA2939492C (en) 2019-03-19

Similar Documents

Publication Publication Date Title
MX2011012047A (es) Inmunoglobulinas humanas anti-cd52.
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
PH12013500990A1 (en) Neutralizing anti-ccl20 antibodies
UA117901C2 (uk) Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
SA519410565B1 (ar) (ctla-4)أجسام مضادة أحادية النسيلة جديدة لبروتين مرتبط بخلية ليمفاوية تائية سامة للخلايا 4
SG10201906762YA (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2020069184A3 (en) Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
JP2014518615A5 (cg-RX-API-DMAC7.html)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
RU2014108208A (ru) Мыши с гуманизированной универсальной легкой цепью
MX2009003838A (es) Anticuerpos anti-cd20 y metodos de uso.
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
UA114879C2 (uk) Антитіло до cd38 для лікування раку
Hristodorov et al. Recombinant H22 (scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody: A potential strategy to enhance anti-TNF therapy
MX2021008672A (es) Competidores de cd31 y usos de los mismos.
RU2019100102A (ru) Гуманизированные и химерные моноклональные антитела против cd81
JP2019517813A5 (cg-RX-API-DMAC7.html)
TH143301A (th) นิวทรอลไลซ์ซิ่ง แอนติ-CCL-20 แอนติบอดี้ (NEUtralizing Anti-CCL-20 Antibodies)
NZ810163A (en) Mice that make binding proteins comprising vl domains
NZ769571A (en) Antibodies binding pd-1 and uses thereof
HK1189899A (en) Neutralizing anti-ccl20 antibodies
NZ780754A (en) Antigen-binding proteins that activate the leptin receptor
NZ780754B2 (en) Antigen-binding proteins that activate the leptin receptor
NZ758252A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration